Upper Gastrointestinal Tract Bleeding From Oral Potassium Chloride

Strom, Brian L.

doi:10.1001/archinte.1987.00370050146025

Cited by 19 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the 25 hospitalized patients who received wax matrix KCI, 20 (80%) were at increased risk for upper gastrointestinal illness due to history of peptic ulcer disease (7 patients), renal failure (3), alcoholism (3), steroid or anticoagulant therapy ( l ) , or a combination of these factors (6). Among the 16 hospitalized users of microencapsulated KCI, 12 (75%) were at increased risk for such illness due to history of ulcer disease (6), alcoholism ( l ) , steroid or anticoagulant therapy (3), or a combination of these factors (2).…”

Section: Resultsmentioning

confidence: 99%

A Comparison of Wax Matrix and Microencapsulated Potassium Chloride in Relation to Upper Gastrointestinal Illness Requiring Hospitalization

Jick

Walker

et al. 1989

Pharmacotherapy

View full text Add to dashboard Cite

The frequency of hospitalization for documented upper gastrointestinal illness among recipients of either wax matrix or microencapsulated potassium chloride was similar in a study in which clinics were randomly assigned to dispense one or the other preparation. The results indicate that there is no material difference between the two preparations in relation to serious upper gastrointestinal illness.

show abstract

Section: Resultsmentioning

confidence: 99%

A Comparison of Wax Matrix and Microencapsulated Potassium Chloride in Relation to Upper Gastrointestinal Illness Requiring Hospitalization

Jick

Walker

et al. 1989

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Although, no significant correlation between steroid usage and gastrointestinal bleeding has been found in clinical studies, yet histamine H2 antagonists and proton pump inhibitors are commonly prescribed to minimize the risk of gastric ulcers, hemorrhage, and other rare gastrointestinal problems such as pancreatitis, colon perforation, and fatty liver disease [43][44][45].…”

Section: Gastrointestinalmentioning

confidence: 99%

Corticosteroids in Neuro-Oncology: Management of Intracranial Tumors and Peritumoral Edema

Ahmed¹

2021

Corticosteroids - A Paradigmatic Drug Class

View full text Add to dashboard Cite

Corticosteroids have been in use for decades and are one of the most prescribed drugs in all specialties of medicine. Jerome Posner, in his classic textbook “Neurological Complications of Cancer,” refers to corticosteroids as widely used drugs in neuro-oncology leading to a remarkable decline in perioperative mortality and morbidity rates. Being the most powerful class of tumor-induced-edema reducing agents, they are adjuvant to chemotherapy and are also known to reduce the risk of encephalopathy and other associated neurological deficits in patients undergoing radiation therapy. They have been widely used in higher-than-normal doses in the management of pathologic, immunological, and inflammatory conditions and various other diseases. Novel insights into the mechanisms of action of corticosteroids and their effects on cancer patients are extensively being studied. While substantial clinical improvements can be seen in cancer patients, corticosteroids are also associated with adverse and well-characterized side effects leading to immediate as well as long-term complications in patients. This chapter reviews the clinical aspects of corticosteroid therapy used in neuro-oncological conditions and its effects on peritumoral edema. Although there is currently insufficient information on appropriate use, in most cases, corticosteroids are used in a supraphysiological and pharmacological manner to minimize the symptoms of cerebral edema. Due to limited clinical studies and evident side effects presenting synonymously with corticosteroid therapy, the emerging role of steroid-sparing drugs such as corticotrophin-releasing factors, tyrosine kinase inhibitors, and VEGF inhibitors will also be discussed.

show abstract

A Population-Based Study of Stevens-Johnson Syndrome

Strom¹

1991

Arch Dermatol

Self Cite

112

View full text Add to dashboard Cite

To determine the incidence of Stevens-Johnson syndrome, a descriptive epidemiology study was performed using computerized Medicaid billing data from 1980 to 1984 from the states of Michigan, Minnesota, and Florida. The ratio of persons hospitalized with a discharge diagnosis of erythema multiforme (ICD-9-CM code 695.1) to persons with any claim for medical service was first used as an estimate of the incidence rate of the disease. Then, since the ICD-9-CM code for erythema multiforme includes other illnesses in addition to Stevens-Johnson syndrome and because these illnesses are frequently misdiagnosed, the information provided by a review of medical records for a subset of cases of erythema multiforme was used to determine the proportion of patients with true Stevens-Johnson syndrome. The incidence rates of Stevens-Johnson syndrome were 7.1 (6.1 to 8.2), 2.6 (1.6 to 4.0), and 6.8 (4.3 to 10.3) per million per year in each state, respectively. Penicillins, especially aminopenicillins, were frequently used in the 19 patients judged to be true cases of Stevens-Johnson syndrome. In conclusion, Stevens-Johnson syndrome is a uncommon condition. The excess risk of Stevens-Johnson syndrome due to any drug must, therefore, be very low.

show abstract

Upper Gastrointestinal Tract Bleeding From Oral Potassium Chloride

Cited by 19 publications

References 16 publications

A Comparison of Wax Matrix and Microencapsulated Potassium Chloride in Relation to Upper Gastrointestinal Illness Requiring Hospitalization

A Comparison of Wax Matrix and Microencapsulated Potassium Chloride in Relation to Upper Gastrointestinal Illness Requiring Hospitalization

Corticosteroids in Neuro-Oncology: Management of Intracranial Tumors and Peritumoral Edema

A Population-Based Study of Stevens-Johnson Syndrome

Contact Info

Product

Resources

About